Drug aimed at fixing bone marrow after transplant falls short in early study

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of poor graft function defined as: * Patient ≥ day+60 after allo-HCT, * Persisting thrombocytopenia on two different samples over at least two weeks (platelet \< 30G/L with transfusion requirement) +/- neutropenia (ANC \<1G/L) +/- anemia (Hb \<8g/dL or transfusion requirement), * Full donor chimerism on whole blood (≥ 95%), * Biopsy proven hypocellular marrow without evidence of myelodysplasia * No evidence for relapse, * No evidence for active acute or chronic graft versus host disease, * Absence of active viral infection (EBV, CMV, ADENOVIRUS, PARVOVIRUS B19), * Absence of B9/B12 deficiency, * Absence of hypothyroidism, * Absence of hypogonadism, * Absence of dialysis, * Absence of thrombotic microangiopathy, * Absence of macrophage activation syndrome, * No other known causes of poor graft function. * Written informed consent must be obtained before any study-trial specific procedure are performed, * Affiliation to a social security system. Exclusion Criteria: * Criteria for poor graft function not fulfilled (see above), * Patients aged less than 6 years old (or unable to swallow), * Hepatic impairment (Child-Pugh ≥ 5), * Patients with bone morrow fibrosis, * Patients with a cytogenetic abnormality of chromosome 7 * Hypersensitivity to eltrombopag or to any of the excipients, * Patients with any contra-indication to eltrombopag, filgrastim, * Unable to understand the investigational nature of the study or give informed consent, * History of congestive heart failure, arrhythmia requiring chronic treatment, arterial or venous, * Thrombosis (not excluding line thrombosis) within the last 1 year, or myocardial infarction within 3 months before enrollment, * ECOG Performance Status of 3 or greater, * Pregnant and/or lactating women, * Freedom privacy.